PriceTargets.com logo

NASDAQ:KTRA - Kintara Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $4.67
  • Forecasted Upside: 348.72 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$1.04 As of 10/20/2021 05:00 PM ET
▲ +0.02 (1.96%)

This chart shows the closing price for KTRA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Kintara Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KTRA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KTRA

Analyst Price Target is $4.67
▲ +348.72% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Kintara Therapeutics in the last 3 months. The average price target is $4.67, with a high forecast of $6.00 and a low forecast of $3.00. The average price target represents a 348.72% upside from the last price of $1.04.

This chart shows the closing price for KTRA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in Kintara Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/28/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/27/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/25/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/23/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/23/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/22/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/20/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/8/2021Maxim GroupInitiated CoverageBuy$3.00High
9/30/2021AegisLower Price TargetBuy$7.00 ➝ $5.00Low
9/28/2021HC WainwrightInitiated CoverageBuy$6.00High
7/2/2021Maxim GroupReiterated RatingBuy$6.00N/A
2/3/2021AegisBoost Price TargetBuy$6.00 ➝ $7.00High
11/20/2020Maxim GroupInitiated CoverageBuy$3.00High
10/1/2020AegisReiterated RatingBuy$6.00High
9/14/2020AegisInitiated CoverageBuy$6.00High
7/28/2020Maxim GroupReiterated RatingBuy$2.00Medium
6/23/2020Maxim GroupInitiated CoverageBuy$2.00Medium
6/6/2020Maxim GroupInitiated CoverageBuy$2.00High
5/14/2020Maxim GroupReiterated RatingBuy$2.00Low
11/15/2019Maxim GroupReiterated RatingBuyLow
9/6/2019Maxim GroupInitiated CoverageBuyHigh
7/11/2019Dawson JamesReiterated RatingBuyHigh
5/23/2018HC WainwrightSet Price TargetBuy$120.00Medium
1/4/2018HC WainwrightSet Price TargetBuy$120.00Medium
11/29/2017HC WainwrightSet Price TargetBuy$120.00Low
10/16/2017HC WainwrightSet Price TargetBuy$120.00N/A
10/5/2017HC WainwrightReiterated RatingBuy$120.00N/A
9/11/2017Maxim GroupReiterated RatingHoldHigh
8/14/2017Maxim GroupDowngradeBuy ➝ HoldLow
8/8/2017Dawson JamesReiterated RatingBuyHigh
6/24/2017HC WainwrightSet Price TargetBuy$120.00Low
6/23/2017Maxim GroupReiterated RatingBuy$110.00Low
5/30/2017HC WainwrightReiterated RatingBuy$120.00Medium
5/25/2017Maxim GroupSet Price TargetBuy$110.00Medium
4/13/2017Maxim GroupSet Price TargetBuy$110.00High
4/5/2017Maxim GroupReiterated RatingBuy$110.00Low
1/26/2017Maxim GroupReiterated RatingBuy$110.00N/A
1/5/2017AegisInitiated CoverageBuy$160.00N/A
(Data available from 10/20/2016 forward)

News Sentiment Rating

-0.19 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/24/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/23/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/23/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/22/2021
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 3 very negative mentions
Mentions as of
7/22/2021
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
8/21/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/20/2021
  • 0 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 5 very negative mentions
Mentions as of
10/20/2021

Current Sentiment

  • 0 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 5 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Kintara Therapeutics logo
Kintara Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of new cancer therapies. It focuses on VAL-083 and REM-001 pipelines. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.
Read More

Today's Range

Now: $1.04
Low: $0.92
High: $1.04

50 Day Range

MA: $1.24
Low: $0.76
High: $1.57

52 Week Range

Now: $1.04
Low: $0.74
High: $3.35

Volume

3,588,101 shs

Average Volume

1,255,297 shs

Market Capitalization

$33.92 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.53

Frequently Asked Questions

What sell-side analysts currently cover shares of Kintara Therapeutics?

The following Wall Street sell-side analysts have issued reports on Kintara Therapeutics in the last twelve months: Aegis, HC Wainwright, and Maxim Group.
View the latest analyst ratings for KTRA.

What is the current price target for Kintara Therapeutics?

3 Wall Street analysts have set twelve-month price targets for Kintara Therapeutics in the last year. Their average twelve-month price target is $4.67, suggesting a possible upside of 348.7%. HC Wainwright has the highest price target set, predicting KTRA will reach $6.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $3.00 for Kintara Therapeutics in the next year.
View the latest price targets for KTRA.

What is the current consensus analyst rating for Kintara Therapeutics?

Kintara Therapeutics currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe KTRA will outperform the market and that investors should add to their positions of Kintara Therapeutics.
View the latest ratings for KTRA.

How do I contact Kintara Therapeutics' investor relations team?

Kintara Therapeutics' physical mailing address is 12707 HIGH BLUFF DR. SUITE 200, SAN DIEGO CA, 92130. The company's listed phone number is (858) 350-4364 and its investor relations email address is [email protected] The official website for Kintara Therapeutics is www.kintara.com.